Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Introduction The structural similarities between
2025-01-02

Introduction The structural similarities between puromycin (1, Fig. 1) and the aminoacyl adenyl terminal of aminoacyl–tRNA allow it to terminate the protein synthesis process by causing premature release of a polypeptide from the ribosome [1], [2]. Tremendous progress in the study of puromycin an
-
Cancers that responded to immune checkpoint
2024-12-31

Cancers that responded to immune checkpoint inhibitors were shown to present a type I interferon (IFN) signature in the TME 33, 34. Type I IFNs positively regulate the expression of tumor antigens and their crosspresentation by DCs to tumoricidal CTLs. Furthermore, CD8+ T cell develops full effector
-
br Patients and methods The severity of disease documented a
2024-12-31

Patients and methods The severity of disease documented at each outpatient visit was graded according to the modified Osserman classification: grade I, focal disease (e.g. restricted to ocular muscles); grade II, generalised disease that is mild (IIa) or moderate (IIb); grade III, severe generali
-
Alkylating agent br Patients and methods The severity of dis
2024-12-31

Patients and methods The severity of disease documented at each outpatient visit was graded according to the modified Osserman classification: grade I, focal disease (e.g. restricted to ocular muscles); grade II, generalised disease that is mild (IIa) or moderate (IIb); grade III, severe generali
-
The relatively high concentration of HT used in this
2024-12-31

The relatively high concentration of 5-HT used in this study (100 µM) is consistent with the concentrations used in other published ex vivo studies (Ropert and Guy, 1991, Passani et al., 1994, Shen and Andrade, 1998). In our paradigm 5-HT was focally applied at the surface of the slice via a fast pe
-
Although the earlier studies focused
2024-12-30

Although the earlier studies focused on the antioxidant capacity of tocopherols, ascorbic colometric buy and carotenoids, then it was noticed that phenolic compounds were more powerful than others (Rice-Evans, Miller, & Paganga, 1996). Phenolic compounds, the most numerous and ubiquitous groups of
-
To date attention has been directed
2024-12-30

To date, attention has been directed towards new molecular targets in luminal phenotype (ER-positive), such as CDK4/6 and, to a lesser extent, androgen receptor (AR) pathways [8]. While the role of CDK4/6 has been elucidated and their inhibitors have shown a benefit in luminal BC, the role of AR in
-
br Introduction Our ability to see our surrounding relies
2024-12-30

Introduction Our ability to see our surrounding relies directly on the integrity of the anatomical structures composing our eyes. One of these key components is the cornea, consisting of the outer layer of the eye. Its transparency is crucial for light transmission to the retina and allows proper
-
G has been shown to participate in various
2024-12-30

Gβγ has been shown to participate in various MT-dependent processes such as cell growth and differentiation [15,[21], [22], [23], [24], [25], [26]]. G-protein β-subunit anti-sense oligonucleotides have been shown to inhibit cell proliferation and cause disorganization of the mitotic spindle in mamma
-
Besides its multiple peripheral effects adiponectin may
2024-12-30

Besides its multiple peripheral effects adiponectin may ameliorate insulin resistance by acting in the brain, and intracerebroventricular administration of adiponectin in rodents decreases body weight by stimulating energy expenditure [13]. Adiponectin most likely crosses the blood-CSF-barrier (BCB)
-
aristocort australia The assay performance was estimated usi
2024-12-30

The assay performance was estimated using Z′-factors (plotted in Fig. 2A) according to Zhang et al. calculated for each plate comparing positive (in the absence of an inhibitor) and negative controls (in the presence of an AdK inhibitor). The mean Z′-factor±SD was determined to be 0.7±0.1, indicativ
-
However for a molecular target to be
2024-12-30

However, for a molecular target to be useful in AD, it must rescue behavioral as well as biochemical insults. In humans, AD memory impairments typically declare themselves initially as disruption of episodic memory and consolidation of new memories, eventually progressing to global cognitive decline
-
The first natural product described as LO inhibitor was the
2024-12-30

The first natural product described as 5-LO inhibitor was the polyphenol nordihydroguaiaretic NS3694 from the Mexican dessert plant Larrea divaricata in 1981 (Bokoch and Reed, 1981), short after the initial identification of 5-LO in 1979 (Borgeat and Samuelsson, 1979). Long time before mPGES-1 was
-
By performing knockdown of AXL once HER cancer cells have
2024-12-27

By performing knockdown of AXL once HER2+ cancer CGP 35348 have achieved lung colonization, we demonstrated that AXL contributes to the establishment of macrometastases. While inhibition of AXL impairs the efficiency of metastasis, the later finding has major clinical implications since pharmacologi
-
What can we learn about the anticancer
2024-12-27

What can we learn about the anticancer therapeutic efficacy of Aurora kinase inhibitors from our experience with the Bcr-Abl inhibitors and the long term clinical consequence of their use in treating leukemias? As discussed, all Aurora kinase inhibitors developed to date are ATP-competitive inhibito
15709 records 49/1048 page Previous Next First page 上5页 4647484950 下5页 Last page